Skip to main content

Table 2 Bayesian estimation of treatment effects of DXM20 vs DXMSoc across baseline subsets, looking for treatment-by-subset interactions

From: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial

Subsets

Posterior quantities

 

HR death, 95% credible interval

Pr benefit (HR < 0.95)

Pr harm (HR > 1.05)

HR ratio (95% credible int)

Pr interaction (HR ratio > 1.2)

All

0.95 (0.66–1.37)

0.511

0.290

  

Age, years

  < 70

0.68 (0.37–1.23)

0.865

0.077

1.00

0.84

 \(\ge \) 70

1.15 (0.72–1.83)

0.22

0.64

1.69 (0.79–3.66)

 

Days since symptoms

  < 7

0.59 (0.46–0.75)

0.999

 < 0.0001

1.00

0.99

 \(\ge \) 7

1.16 (1.06–1.28)

 < 0.0001

0.981

1.99 (1.52–2.56)

 

Body temperature, °C

    

0.58

  < 38

0.96 (0.63–1.45)

0.487

0.335

1.00

 

 \(\ge \) 38

0.93 (0.47–1.71)

0.526

0.357

0.97 (0.49–1.79)

 

Inflammationa

 No

0.94 (0.30–2.79)

0.507

0.422

1.00

0.68

 Yes

0.91 (0.44–2.16)

0.541

0.366

0.97 (0.44–2.59)

 

CRP, mg/L

  < 135

0.93 (0.51–1.67)

0.533

0.340

1.00

0.76

 \(\ge \) 135

1.33 (0.74–2.38)

0.129

0.789

1.43 (0.79–2.59)

 

Ferritin, μg/L

  < 1120

1.87 (0.96–3.57)

0.023

0.957

1.00

0.99

 \(\ge \) 1120

0.42 (0.21–0.84)

0.99

 < 0.001

0.22 (0.09–0.58)

 

Ddimers, ng/mL

  < 940

0.63 (0.34–1.17)

0.906

0.051

1.00

0.99

 \(\ge \) 940

1.52 (0.87–2.72)

0.050

0.904

2.41 (1.38–4.29)

 

IMV

 No

0.90 (0.53–1.43)

0.600

0.254

1.00

0.65

 Yes

1.02 (0.57–1.84)

0.401

0.463

1.14 (0.54–2.44)

 

SAPS II

  < 33

0.91 (0.43–1.88)

0.55

0.35

1.00

0.67

 \(\ge \) 33

0.97 (0.63–1.51)

0.46

0.36

1.07 (0.46–2.57)

 

Remdesivir use

 No

1.15 (0.75–1.75)

0.191

0.660

1.00

0.91

 Yes

0.61 (0.29–1.18)

0.901

0.056

0.54 (0.25–1.03)

 
  1. In each subset, hazard ratio (HR) of death within the first 60 days (with 95% credibility intervals, CrI) were computed, with posterior probability of benefit or harm; then potential heterogeneity in effect across subsets was measured on the ratio of both HR
  2. CRP C reactive protein, O2 oxygen, HFNO High-Flow Nasal Oxygen, CPAP Continuous Positive Airway Pressure, IMV invasive mechanical ventilation, IL6 interleukin 6, SAPS Simplified Acute Physiology Score, HR hazard ratio, Pr probability
  3. aDefined as either ferritin level > 1000 μg/L or CRP > 100 mg/L